JP2020162447A - Container for cell concentration - Google Patents

Container for cell concentration Download PDF

Info

Publication number
JP2020162447A
JP2020162447A JP2019064476A JP2019064476A JP2020162447A JP 2020162447 A JP2020162447 A JP 2020162447A JP 2019064476 A JP2019064476 A JP 2019064476A JP 2019064476 A JP2019064476 A JP 2019064476A JP 2020162447 A JP2020162447 A JP 2020162447A
Authority
JP
Japan
Prior art keywords
cell
accommodating portion
cell concentration
container
elastic member
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019064476A
Other languages
Japanese (ja)
Other versions
JP7226738B2 (en
Inventor
義久 鈴木
Yoshihisa Suzuki
義久 鈴木
薫 尾前
Kaoru Omae
薫 尾前
博史 井川
Hiroshi Igawa
博史 井川
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fukoku Co Ltd
Shiga University of Medical Science NUC
Fukoku KK
Foundation for Biomedical Research and Innovation at Kobe
Original Assignee
Fukoku Co Ltd
Shiga University of Medical Science NUC
Fukoku KK
Foundation for Biomedical Research and Innovation at Kobe
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fukoku Co Ltd, Shiga University of Medical Science NUC, Fukoku KK, Foundation for Biomedical Research and Innovation at Kobe filed Critical Fukoku Co Ltd
Priority to JP2019064476A priority Critical patent/JP7226738B2/en
Priority to PCT/JP2020/012533 priority patent/WO2020196347A1/en
Publication of JP2020162447A publication Critical patent/JP2020162447A/en
Application granted granted Critical
Publication of JP7226738B2 publication Critical patent/JP7226738B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12MAPPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M1/00Apparatus for enzymology or microbiology
    • C12M1/26Inoculator or sampler

Abstract

To provide a container for cell concentration, with which cell concentration may be executed while keeping a closed system with a simple structure, and in which cell concentrate solution may be easily drawn without waste.SOLUTION: There is provided a cell concentration container 10 which is provided with a discharge part 12 at one end of a flexible container body 11, and generates cell concentrate solution in which target cells are precipitated on one end side by being centrifuged while storing cell suspension containing the target cells in a closed state. A container body 11 comprises a first storage part 17 and a second storage part 21 that is provided on a bottom part 19 on one end side of the first storage part 17 in a communicated manner with the first storage part 17 and in which the cell concentrate solution is stored. The bottom part 19 of the first storage part 17 is formed in a downward gradient toward the second storage part 21. The discharge part 12 is provided on an end part of the second storage part 21 in a closed state, but the cell concentrate solution may be drawn from an end 29.SELECTED DRAWING: Figure 1

Description

本発明は細胞懸濁液を収容して遠心分離により濃縮する細胞濃縮用容器に関する。 The present invention relates to a cell concentration container that contains a cell suspension and concentrates by centrifugation.

従来、細胞懸濁液を収容して遠心分離する必要があることから、強度が得やすい硬質容器が多用されていたが、可撓性容器を用いて遠心分離する技術も知られている。
例えば下記特許文献1では、一部又は全部が可撓性を有する容器本体に、大きな容積の第1の収容部と、遠心沈殿物を収容するための小さな容積の第2の収容部とを設けた遠心分離用容器が提案されている。この遠心分離用容器では、第1の収容部の上部にポート部が設けられていて、遠心分離後に第1の収容部と第2の収容部との境界部分の容器壁を外側から密着させることで、ポート部と第2の収容部を非連通状態にして、第2の収容部の細胞を分離したり洗浄したりしていた。
このような容器では、第2の収容部に収容された分離後の目的細胞を第2の収容部から回収するような場合に、容器に変形等が生じると、手間を要するものであった。
Conventionally, since it is necessary to contain a cell suspension and centrifuge it, a hard container having easy to obtain strength has been often used, but a technique of centrifuging using a flexible container is also known.
For example, in Patent Document 1 below, a container body having some or all flexibility is provided with a first storage portion having a large volume and a second storage portion having a small volume for storing centrifugal precipitates. A container for centrifugation has been proposed. In this centrifuge container, a port portion is provided above the first accommodating portion, and after centrifugation, the container wall at the boundary between the first accommodating portion and the second accommodating portion is brought into close contact with the container wall from the outside. Then, the port portion and the second accommodating portion were made in a non-communication state, and the cells in the second accommodating portion were separated and washed.
In such a container, when the target cells after separation contained in the second storage portion are collected from the second storage portion, if the container is deformed or the like, it takes time and effort.

下記特許文献2では、有核細胞と不要細胞とを含む細胞含有液から不要細胞を分離して回収バッグに有核細胞を回収し、または濃縮することが行われていた。この文献では、高遠心力で遠心分離するとともにフィルタによるろ過を用いて分離した後でコニカルチューブなどに移し、さらに遠心分離して単核球が回収されていた。そのため容器の移し替えなどに手間を要していた。 In Patent Document 2 below, unnecessary cells are separated from a cell-containing solution containing nucleated cells and unnecessary cells, and the nucleated cells are collected or concentrated in a collection bag. In this document, mononucleosis was recovered by centrifuging with high centrifugal force, separating by filtration with a filter, transferring to a conical tube or the like, and further centrifuging. Therefore, it took time and effort to transfer the container.

下記特許文献3では、血液の血漿成分、白血球、赤血球等の分離精度を高めるために遠心分離器にかける血液バッグにおいて、容器の上端や下端、更には中腹にチューブを接続して各成分を分離して各チューブから流出させていた。そのため少量の成分の場合には、容器内や回収するまでの経路などに残留して無駄が生じ易かった。 In Patent Document 3 below, in a blood bag to be centrifuged in order to improve the separation accuracy of blood plasma components, leukocytes, red blood cells, etc., each component is separated by connecting a tube to the upper end, the lower end, and the middle abdomen of the container. And it was drained from each tube. Therefore, in the case of a small amount of components, waste is likely to occur because they remain in the container or in the route until collection.

さらに、下記特許文献4では、容量部Aと容量部Bからなり、容量部Aの下部に容量部Bがあり、容量がA>Bで、容量部Aと容量部Bが容易に分離又は分断可能に設けられた遠心分離用容器が提案されている。しかしながら、この遠心分離容器をバッグから分離した容量部Bの細胞をシリンジ等で取り出すようにしているため、分離後の細胞を回収するのに手間を要していた。 Further, in Patent Document 4 below, it is composed of a capacity part A and a capacity part B, a capacity part B is provided below the capacity part A, the capacity is A> B, and the capacity part A and the capacity part B are easily separated or divided. Possible centrifuge containers have been proposed. However, since the cells in the volume B separated from the bag are taken out from the centrifuge container by a syringe or the like, it takes time and effort to collect the separated cells.

特開2011−125813号公報Japanese Unexamined Patent Publication No. 2011-125813 国際公開WO2005/035737号公報International Publication WO2005 / 035737 特開平08−82621号公報Japanese Patent Application Laid-Open No. 08-82221 特開2008−220319号公報Japanese Unexamined Patent Publication No. 2008-220319

以上のように、上記何れの技術であっても、可撓性を有する容器を用いて遠心分離により沈降する細胞を回収したり濃縮したりする従来のシステムでは、容器の移し替えなどの際に手間を要したり、無駄が生じたりし易かった。 As described above, in any of the above techniques, in the conventional system for collecting or concentrating the cells that settle by centrifugation using a flexible container, when the container is transferred or the like, the cells are transferred. It was easy to take time and waste.

そこで本発明では、簡易な構造で閉鎖系を保ちつつ細胞濃縮を行うことができるとともに、細胞濃縮液を容易に無駄なく抜き取りし易い細胞濃縮用容器を提供することを目的とする。 Therefore, an object of the present invention is to provide a cell concentration container capable of concentrating cells while maintaining a closed system with a simple structure and easily extracting the cell concentrate without waste.

上記目的を達成する本発明の細胞濃縮用容器は、可撓性の容器本体の一端部に排出部を有し、目的細胞を含有する細胞懸濁液が密封状態で収容されて遠心分離されることで、一端側に目的細胞が沈降して細胞濃縮液が生成される細胞濃縮用容器であって、容器本体は、第1収容部と、第1収容部の一端側の底部に第1収容部と連通して設けられて細胞濃縮液が貯留される第2収容部と、を有し、第1収容部の底部は、第2収容部側に向けて下り勾配に形成され、排出部は、第2収容部の一端部に設けられて先端から細胞濃縮液を抜き取り可能に閉塞されていることを特徴としている。
本発明では、目的細胞が単核球であって、単核球を含有する細胞懸濁液から単核球を濃縮する細胞濃縮用容器であってもよい。
The cell concentration container of the present invention that achieves the above object has a discharge portion at one end of a flexible container body, and a cell suspension containing the target cells is contained in a sealed state and centrifuged. This is a cell concentration container in which the target cells settle on one end side to generate a cell concentrate, and the container body is first stored in the first storage portion and the bottom of the first storage portion on the one end side. It has a second accommodating portion that is provided in communication with the portion and stores the cell concentrate, and the bottom of the first accommodating portion is formed with a downward slope toward the second accommodating portion side, and the discharging portion is , It is characterized in that it is provided at one end of the second accommodating portion and is occluded so that the cell concentrate can be extracted from the tip.
In the present invention, the target cell may be a mononucleosis and may be a cell concentration container for concentrating mononucleosis from a cell suspension containing mononucleosis.

本発明の細胞濃縮用容器は、第2収容部が可撓性チューブにより形成され、排出部が第2収容部を外側から加圧して閉塞されていてもよい。
また本発明の細胞濃縮用容器は、排出部が少なくとも先端に流路を有する硬質部材を備え、抜取具を貫通可能な弾性部材により流路が閉塞されていてもよい。この場合、弾性部材にスリットが設けられているのが好適である。
さらに弾性部材を貫通した抜取具の先端開口を、容器本体内における弾性部材の隣接位置に配置可能に構成されていることが好ましい。
In the cell concentration container of the present invention, the second storage portion may be formed of a flexible tube, and the discharge portion may be closed by pressing the second storage portion from the outside.
Further, the cell concentration container of the present invention may include a hard member having a flow path at least at the tip of the discharge portion, and the flow path may be blocked by an elastic member capable of penetrating the extraction tool. In this case, it is preferable that the elastic member is provided with a slit.
Further, it is preferable that the tip opening of the extraction tool penetrating the elastic member can be arranged at a position adjacent to the elastic member in the container body.

本発明の細胞濃縮用容器によれば、容器本体が可撓性を有するので、密封状態で容積を増減でき、簡易な構造で閉鎖系を保ちつつ細胞濃縮のための各操作を行うことができる。
そして、容器本体には、第1収容部の一端側の底部に第2収容部が連通して設けられ、第1収容部の一端側の底部が第2収容部側に下り勾配で形成され、さらに第2収容部の一端部に排出部が設けられて先端から細胞濃縮液を抜き取り可能に閉塞されている。
そのため、遠心分離により目的細胞が一端側に沈降して集まることで、第2収容部における排出部の先端から抜き取り易い位置に細胞濃縮液が生成される。従って、この細胞濃縮液を直接無駄なく抜き取ることができる。しかも、細胞濃縮液を第2収容部、すなわち、細胞濃縮液の集積部位の先端から抜き取るため、可撓性で変形し易い容器本体であっても変形を抑えて抜き取り操作を行い易い。
よって、本発明にあっては、簡易な構造で閉鎖系を保ちつつ細胞濃縮を行うことができるとともに、細胞濃縮液を容易に無駄なく確実に抜き取ることが可能な細胞濃縮用容器を提供することができる。
According to the cell concentration container of the present invention, since the container body has flexibility, the volume can be increased or decreased in a sealed state, and each operation for cell concentration can be performed while maintaining a closed system with a simple structure. ..
Then, the container body is provided with a second accommodating portion communicating with the bottom portion on one end side of the first accommodating portion, and the bottom portion on one end side of the first accommodating portion is formed on the second accommodating portion side with a downward gradient. Further, a discharge portion is provided at one end of the second accommodating portion so that the cell concentrate can be drawn out from the tip and closed.
Therefore, by centrifuging, the target cells settle to one end side and gather, so that the cell concentrate is generated at a position where it can be easily extracted from the tip of the discharge portion in the second accommodating portion. Therefore, this cell concentrate can be directly withdrawn without waste. Moreover, since the cell concentrate is extracted from the second accommodating portion, that is, the tip of the accumulation site of the cell concentrate, it is easy to suppress the deformation and perform the extraction operation even in the flexible and easily deformable container body.
Therefore, in the present invention, it is provided to provide a cell concentration container capable of concentrating cells while maintaining a closed system with a simple structure and easily and reliably withdrawing the cell concentrate without waste. Can be done.

本発明の細胞濃縮用容器において、目的細胞が単核球であって、単核球を含有する細胞懸濁液から単核球を濃縮すれば、細胞濃縮液を無駄なく抜き取って有効に使用することができる。
本発明の細胞濃縮用容器において、第2収容部が可撓性チューブにより形成され、排出部が第2収容部を外側から加圧して閉塞する構成であれば、外側から第2収容部を容易に開閉して細胞濃縮液を抜き取ることができ、操作性がよい。
In the cell concentration container of the present invention, if the target cell is a mononucleosis and the mononucleosis is concentrated from the cell suspension containing the mononucleosis, the cell concentrate can be extracted without waste and used effectively. be able to.
In the cell concentration container of the present invention, if the second accommodating portion is formed of a flexible tube and the discharge portion presses and closes the second accommodating portion from the outside, the second accommodating portion can be easily operated from the outside. It can be opened and closed to remove the cell concentrate, which is easy to operate.

本発明の細胞濃縮用容器において、排出部が先端に流路を有する硬質部材を備え、抜取具を貫通させることができる弾性部材により流路が閉塞されていれば、抜取具を貫通させることで容易に細胞濃縮液を抜き取ることができ、しかも抜取具を貫通させる際に硬質部材を支持して操作することができるため操作性がよい。また、硬質部材の内径に弾性部材を装着するため、嵌合代、すなわち、硬質部材の内径に対する弾性部材の封止力をコントロールすることが容易となり、確実な封止を行うことができる。なお、弾性部材にスリットが設けられていれば、抜取具が太くても弾性部材を貫通させることができ、細胞濃縮液をより大径の流路から抜き取ることができ、抜き取る際に細胞に損傷等を与えることを防止できる。よって、確実な封止力を得ながら、細胞濃縮液の抜き取りを容易に行うことができる。
さらに、弾性部材を貫通した抜取具の先端開口を弾性部材の隣接位置に配置可能に構成していれば、細胞濃縮液を抜取具により抜き取る際、内部に細胞濃縮液が残留し難く、無駄なく抜き取ることができる。
In the cell concentration container of the present invention, if the discharge portion is provided with a hard member having a flow path at the tip and the flow path is blocked by an elastic member capable of penetrating the extraction tool, the extraction tool can be penetrated. The cell concentrate can be easily extracted, and the hard member can be supported and operated when penetrating the extraction tool, so that the operability is good. Further, since the elastic member is mounted on the inner diameter of the hard member, it becomes easy to control the fitting allowance, that is, the sealing force of the elastic member with respect to the inner diameter of the hard member, and reliable sealing can be performed. If the elastic member is provided with a slit, the elastic member can be penetrated even if the extraction tool is thick, and the cell concentrate can be extracted from a larger diameter flow path, and the cells are damaged during extraction. Etc. can be prevented from being given. Therefore, the cell concentrate can be easily withdrawn while obtaining a reliable sealing force.
Further, if the tip opening of the extraction tool penetrating the elastic member can be arranged at a position adjacent to the elastic member, the cell concentration solution is unlikely to remain inside when the cell concentration solution is extracted by the extraction tool, and there is no waste. Can be extracted.

本発明の実施形態に係る細胞濃縮用容器の正面図である。It is a front view of the container for cell concentration which concerns on embodiment of this invention. 本発明の実施形態に係る細胞濃縮用容器の排出部の構成を説明する図である。It is a figure explaining the structure of the discharge part of the cell concentration container which concerns on embodiment of this invention. 本発明の実施形態に係る細胞濃縮用容器を遠心分離機に装着する際に使用するアダプタを示し、(a)は断面図、(b)は底面図である。An adapter used when mounting the cell concentration container according to the embodiment of the present invention on a centrifuge is shown, (a) is a cross-sectional view, and (b) is a bottom view.

以下、本発明の実施形態について図を用いて詳細に説明する。
本実施形態の遠心分離用容器は、目的細胞を含有する細胞懸濁液を密封状態で収容して遠心分離することで、目的細胞が一端側に沈降して濃縮されて細胞濃縮液が生成される容器である。
Hereinafter, embodiments of the present invention will be described in detail with reference to the drawings.
In the centrifuge container of the present embodiment, the cell suspension containing the target cells is contained in a sealed state and centrifuged, so that the target cells settle to one end side and are concentrated to generate a cell concentrate. It is a container.

本実施形態の細胞懸濁液は、生体から採取されて目的細胞を含有する懸濁液であり、生体から採取された液、又は、生体から採取された液を遠心分離、濾過等の各種の方法で分離して得られた一部の成分からなる液やその希釈液などである。本実施形態では、髄液や末梢血などから赤血球が分離されて目的細胞としての単核球が含有された液である。 The cell suspension of the present embodiment is a suspension collected from a living body and containing target cells, and various kinds of solutions such as centrifugation and filtration of a solution collected from a living body or a solution collected from a living body are used. A liquid consisting of a part of the components obtained by separation by the method or a diluted liquid thereof. In the present embodiment, it is a liquid in which red blood cells are separated from cerebrospinal fluid, peripheral blood, etc. and contains monocytes as target cells.

本実施形態の細胞濃縮用容器10は、図1に示すように、可撓性の容器本体11と、容器本体11の一端部に設けられた細胞濃縮液の排出部12と、他端部に接続された連結チューブ13と、他端部に設けられた懸垂部15とを備えている。 As shown in FIG. 1, the cell concentration container 10 of the present embodiment has a flexible container body 11, a cell concentrate discharge portion 12 provided at one end of the container body 11, and the other end. It includes a connected connecting tube 13 and a suspension portion 15 provided at the other end.

容器本体11は、第1収容部17と、第1収容部17の一端側の底部19に第1収容部17と連通して設けられ、遠心分離時に細胞濃縮液が生成して集積される第2収容部21と、を有している。本実施形態では、第1収容部17と第2収容部21とが接合部23を介して接合されている。 The container body 11 is provided at the first accommodating portion 17 and the bottom portion 19 on one end side of the first accommodating portion 17 in communication with the first accommodating portion 17, and a cell concentrate is generated and accumulated during centrifugation. It has two accommodating portions 21 and. In the present embodiment, the first accommodating portion 17 and the second accommodating portion 21 are joined via the joining portion 23.

第1収容部17は可撓性フィルムが互いに対向して周囲で密封されることでバッグ状に形成されている。第1収容部17の一端側には、第1収容部17の軸Lに沿って幅が縮小する縮小部25が設けられている。縮小部25の端部には接合部23を介して第2収容部21が接合されていて、第1収容部17の底部19が第2収容部21側に向けて下り勾配に形成されている。 The first accommodating portion 17 is formed in a bag shape by the flexible films facing each other and being sealed around. On one end side of the first accommodating portion 17, a reducing portion 25 whose width is reduced along the axis L of the first accommodating portion 17 is provided. A second accommodating portion 21 is joined to the end of the reduced accommodating portion 25 via a joint portion 23, and the bottom portion 19 of the first accommodating portion 17 is formed in a downward slope toward the second accommodating portion 21 side. ..

第1収容部17の他端部側には、細胞懸濁液を第1収容部17内に供給したり、分離液や洗浄液等を排出したりするために他の器具と連結可能な複数の連結チューブ13が連結されるともに、細胞濃縮用容器10を他の部材に安定して吊り下げるための懸垂部15が設けられて密封されている。 On the other end side of the first accommodating portion 17, a plurality of devices that can be connected to other instruments for supplying a cell suspension into the first accommodating portion 17 and discharging a separation solution, a washing solution, or the like. The connecting tube 13 is connected, and a suspension portion 15 for stably suspending the cell concentration container 10 from another member is provided and sealed.

第2収容部21は、可撓性チューブにより形成されていて、接合部23を介して第1収容部17に接合され、第1収容部17から軸Lに沿って一端側へ延びている。
接合部23は、成形体からなり、外周面が第1収容部17における縮小部25の内側に収容されて気密に接合され、軸L方向に突出した筒部27に第2収容部21が外嵌して気密に接合されている。
接合部23の内部には第2収容部21の一部を構成する貫通孔が軸L方向に設けられていて、第2収容部21が第1収容部17と連通している。すなわち、接合部23、筒部27の内部容積を含めて、第2収容部21と見做すこともできる。
The second accommodating portion 21 is formed of a flexible tube, is joined to the first accommodating portion 17 via the joint portion 23, and extends from the first accommodating portion 17 to one end side along the axis L.
The joint portion 23 is made of a molded body, and the outer peripheral surface is accommodated inside the reduced portion 25 in the first accommodating portion 17 and airtightly joined, and the second accommodating portion 21 is outside the tubular portion 27 protruding in the axial L direction. It is fitted and airtightly joined.
Inside the joint portion 23, a through hole forming a part of the second accommodating portion 21 is provided in the axial L direction, and the second accommodating portion 21 communicates with the first accommodating portion 17. That is, it can be regarded as the second accommodating portion 21 including the internal volumes of the joint portion 23 and the tubular portion 27.

排出部12は、第2収容部21の一端部に設けられ、第2収容部21の一端部を気密に閉塞するとともに、先端29から細胞濃縮液を抜き取り可能に構成されている。
この排出部12は、図2に示すように、可撓性チューブ状の第2収容部21が外嵌して気密に接合されるとともに、内部に第2収容部21の内部と連通する流路31を有する成形体からなる硬質部材33と、流路31を気密に閉塞する弾性部材35と、弾性部材35及び硬質部材33の先端を外側から囲んで加圧したうえで閉塞可能なキャップ37と、硬質部材33の近接位置で第2収容部21を外側から圧迫して密封するクレンメ等のクリップ39と、を有する。硬質部材33は少なくとも第1収容部17及び第2収容部21よりも硬質に形成されている。
The discharge portion 12 is provided at one end of the second accommodating portion 21, and is configured so that one end of the second accommodating portion 21 is airtightly closed and the cell concentrate can be extracted from the tip 29.
As shown in FIG. 2, the discharge portion 12 has a flexible tube-shaped second accommodating portion 21 that is externally fitted and airtightly joined, and a flow path that communicates with the inside of the second accommodating portion 21 inside. A hard member 33 made of a molded body having 31, an elastic member 35 that airtightly closes the flow path 31, and a cap 37 that can be closed by surrounding the tips of the elastic member 35 and the hard member 33 from the outside and applying pressure. A clip 39 such as a clamp that presses and seals the second accommodating portion 21 from the outside at a position close to the hard member 33. The hard member 33 is formed to be at least harder than the first accommodating portion 17 and the second accommodating portion 21.

本実施形態では、弾性部材35はシリンジの針管や筒先など、各種の抜取具41が貫通可能に形成されている。この弾性部材35には、軸L方向にスリット43が設けられることで、より太い抜取具41が貫通し易くされている。この弾性部材35は、硬質部材33の流路31に配置された状態で、キャップ37が締め込まれることで硬質部材33を介して外周側から加圧圧縮されて密封されるように構成されている。 In the present embodiment, the elastic member 35 is formed so that various extraction tools 41 such as a needle tube and a cylinder tip of a syringe can penetrate. The elastic member 35 is provided with a slit 43 in the L direction of the axis, so that a thicker extraction tool 41 can easily penetrate the elastic member 35. The elastic member 35 is configured to be sealed by being pressure-compressed from the outer peripheral side via the hard member 33 by tightening the cap 37 while being arranged in the flow path 31 of the hard member 33. There is.

本実施形態の排出部12は、遠心分離時に閉塞状態を維持するために、クリップ39により第2収容部21の下端を外側から加圧して閉鎖するとともに、第2収容部21の端部でキャップ37を締め込むことにより、外側から加圧して流路31を密封している。 In order to maintain the closed state at the time of centrifugation, the discharge portion 12 of the present embodiment is closed by pressing the lower end of the second accommodating portion 21 from the outside by the clip 39, and is capped at the end of the second accommodating portion 21. By tightening 37, pressure is applied from the outside to seal the flow path 31.

また本実施形態の排出部12は、抜取具41を排出部12に貫通させた際、抜取具41が硬質部材33やキャップ37等に当接して第2収容部21内への挿入位置が規制されており、抜取具41の先端開口41aが第2収容部21の内部における弾性部材35の隣接位置、すなわち、本実施形態においては、第2収容部21の下方内壁を構成する弾性部材35の第2収容部21内部への露出面近傍に配置することが可能となっている。 Further, in the discharge unit 12 of the present embodiment, when the extraction tool 41 is passed through the discharge unit 12, the extraction tool 41 comes into contact with the hard member 33, the cap 37, etc., and the insertion position into the second accommodating portion 21 is restricted. The tip opening 41a of the extraction tool 41 is located adjacent to the elastic member 35 inside the second accommodating portion 21, that is, in the present embodiment, the elastic member 35 constituting the lower inner wall of the second accommodating portion 21. It is possible to arrange it in the vicinity of the exposed surface inside the second accommodating portion 21.

本実施形態の細胞濃縮用容器10では、第1収容部17、接合部23、第2収容部21、及び硬質部材33がそれぞれ同一の樹脂又は互いに熱溶着可能な樹脂であって、収容される細胞懸濁液及び細胞濃縮液に対してより安全な樹脂により構成されており、各接合部分が熱溶着されている。 In the cell concentration container 10 of the present embodiment, the first accommodating portion 17, the joining portion 23, the second accommodating portion 21, and the hard member 33 are each accommodated as the same resin or a resin that can be heat-welded to each other. It is composed of a resin that is safer for cell suspensions and cell concentrates, and each joint is heat-welded.

本実施形態において、より具体的には、第1収容部17は、エチレン−酢酸ビニル共重合樹脂フィルムから袋状に形成し、接合部23は、エチレン−酢酸ビニル共重合樹脂成形体等から形成し、第2収容部21は、主として、エチレン−酢酸ビニル共重合樹脂製チューブ等から略管状に形成し、硬質部材33は、エチレン−酢酸ビニル共重合樹脂成形体等から構成される。上記の他、ポリエチレン樹脂、ポリプロピレン樹脂、エチレン−プロピレン共重合樹脂、ポリブタジエン樹脂、スチレン−ブタジエン共重合樹脂およびそれらの水素添加樹脂、ポリウレタン樹脂、ならびにそれらの樹脂の混合物などが用途に合わせて使用可能であるが、密着性、熱溶着性を考慮して適用する。密閉性、無菌状態維持、揮発性ガスの発生などを考慮すれば、熱溶着による接合が好ましく、熱溶着性のよい同一素材によって形成することが好ましい。 In the present embodiment, more specifically, the first accommodating portion 17 is formed from an ethylene-vinyl acetate copolymer resin film in a bag shape, and the joint portion 23 is formed from an ethylene-vinyl acetate copolymer resin molded product or the like. The second accommodating portion 21 is mainly formed of an ethylene-vinyl acetate copolymer resin tube or the like in a substantially tubular shape, and the hard member 33 is composed of an ethylene-vinyl acetate copolymer resin molded product or the like. In addition to the above, polyethylene resin, polypropylene resin, ethylene-propylene copolymer resin, polybutadiene resin, styrene-butadiene copolymer resin and their hydrogenated resin, polyurethane resin, and a mixture of these resins can be used according to the application. However, it is applied in consideration of adhesion and heat-weldability. Considering airtightness, maintenance of aseptic condition, generation of volatile gas, etc., bonding by heat welding is preferable, and it is preferable to form the same material having good heat welding property.

このような細胞濃縮用容器10を用いて細胞懸濁液中の目的細胞を濃縮して細胞濃縮液を得るには、予め細胞濃縮用容器10を連結チューブ13及び排出部12を閉塞した状態で滅菌しておき、連結チューブ13から細胞濃縮液と、適宜混合する成分や液と、をシリンジ等の抜取具41を用いて収容して密封する。 In order to concentrate the target cells in the cell suspension using such a cell concentration container 10 to obtain a cell concentrate, the cell concentration container 10 is previously closed with the connecting tube 13 and the discharge portion 12 closed. After sterilization, the cell concentrate and the components and liquids to be appropriately mixed are contained and sealed from the connecting tube 13 using a drawing tool 41 such as a syringe.

この細胞濃縮用容器10を、例えば図3(a)(b)に示すようなアダプタ45を用いて遠心分離機に装着する。アダプタ45は、遠心分離機の収容位置に設けられた治具46に細胞濃縮用容器10を安定して配置するもので、治具46の内面に対応した外周面47を有し、内側には第1収容部17の側周部を支持する内周面48aと、第1収容部17の一端側の縮小部25を支持する傾斜面48bとを有する。傾斜面48bの一端側には、軸方向に貫通して第2収容部21及び排出部12を安定して配置可能な内部配置部49が設けられている。内部配置部49は、第1収容部19の筒部27が配置される小径部49aと、第2収容部21が閉塞されないように例えば巻回するように曲げて収容される大径部49bと、を備えている。 The cell concentration container 10 is attached to the centrifuge using, for example, an adapter 45 as shown in FIGS. 3 (a) and 3 (b). The adapter 45 stably arranges the cell concentration container 10 on the jig 46 provided at the accommodation position of the centrifuge, and has an outer peripheral surface 47 corresponding to the inner surface of the jig 46, and has an outer peripheral surface 47 corresponding to the inner surface of the jig 46. It has an inner peripheral surface 48a that supports the side peripheral portion of the first accommodating portion 17, and an inclined surface 48b that supports the reduced portion 25 on one end side of the first accommodating portion 17. An internal arrangement portion 49 is provided on one end side of the inclined surface 48b so that the second accommodating portion 21 and the discharge portion 12 can be stably arranged so as to penetrate in the axial direction. The internal arrangement portion 49 includes a small diameter portion 49a in which the tubular portion 27 of the first accommodating portion 19 is arranged, and a large diameter portion 49b in which the second accommodating portion 21 is bent so as to be wound so as not to be blocked. , Is equipped.

このアダプタ45を用いて細胞濃縮用容器10を遠心分離機に装着した状態で、遠心分離を行う。
これにより目的細胞が沈降し、順次第2収容部21の排出部12側に集積され、細胞濃縮液が生成される。細胞濃縮液の生成量が第2収容部21の容積より多い場合には、第1収容部17の縮小部25等にも細胞濃縮液が収容されてもよい。後述するクランプ51などで第1収容部17と第2収容部21を仕切る場合には、生成される細胞濃縮液の全量が収まる大きさの第2収容部21を用意して、第2収容部21に収容することが望ましい。
Centrifugation is performed with the cell concentration container 10 attached to the centrifuge using this adapter 45.
As a result, the target cells settle and are sequentially accumulated on the discharge portion 12 side of the second accommodating portion 21, and a cell concentrate is generated. When the amount of the cell concentrate produced is larger than the volume of the second accommodating portion 21, the cell concentrate may be accommodated in the reduced portion 25 or the like of the first accommodating portion 17. When partitioning the first accommodating portion 17 and the second accommodating portion 21 with a clamp 51 or the like described later, a second accommodating portion 21 having a size that accommodates the entire amount of the generated cell concentrate is prepared and the second accommodating portion 21 is provided. It is desirable to accommodate in 21.

所定時間の遠心分離が終了した後、沈殿した細胞が散らないよう注意し、懸垂部15を利用して細胞濃縮用容器10を吊り下げ、図1中に仮想線で示すように、第1収容部17又は第2収容部21の外側からクランプ51で横断する位置を挟むことで、第1収容部17の内部と第2収容部21の内部とを液密に仕切る。
連結チューブ13からクランプ51より第1収容部17の他端部に収容された上清液を抜き取って排出する。
このとき予め容器本体11の側面に、懸垂部15で吊り下げたときの液面の位置を測定する目盛を設けておけば、この目盛りを基準にしてクランプ51により仕切ることで、排出する液量を調整することが可能である。
その後、必要に応じて、他の連結チューブ13から生理食塩水を添加し、同様に懸濁及び遠心分離してクランプ51で仕切って上清液を抜き取ることにより、細胞洗浄を行ってもよい。
After the centrifugation for a predetermined time is completed, care is taken not to disperse the precipitated cells, and the cell concentration container 10 is suspended using the suspension portion 15, and the first accommodation is performed as shown by a virtual line in FIG. By sandwiching a position crossed by the clamp 51 from the outside of the portion 17 or the second accommodating portion 21, the inside of the first accommodating portion 17 and the inside of the second accommodating portion 21 are liquid-tightly partitioned.
The supernatant liquid contained in the other end of the first accommodating portion 17 is extracted from the connecting tube 13 from the clamp 51 and discharged.
At this time, if a scale for measuring the position of the liquid level when suspended by the suspension portion 15 is provided in advance on the side surface of the container main body 11, the amount of liquid discharged by partitioning with the clamp 51 based on this scale. It is possible to adjust.
Then, if necessary, physiological saline may be added from another connecting tube 13, suspended and centrifuged in the same manner, partitioned by a clamp 51, and the supernatant liquid may be withdrawn to wash the cells.

最終の遠心分離を行った後、クランプ51を外して濃縮細胞をタッピング等で外部から解して懸濁させる。
この状態で、シリンジ等の抜取具41を排出部12の先端から挿入して弾性部材35を貫通させ、抜取具41の先端開口41aを第2収容部21の内部における弾性部材35の隣接位置に配置し、第2収容部21内の液を抜き取ることで細胞濃縮液を得ることができる。
After the final centrifugation, the clamp 51 is removed and the concentrated cells are loosened from the outside by tapping or the like and suspended.
In this state, the extraction tool 41 such as a syringe is inserted from the tip of the discharge portion 12 to penetrate the elastic member 35, and the tip opening 41a of the extraction tool 41 is positioned adjacent to the elastic member 35 inside the second accommodating portion 21. A cell concentrate can be obtained by arranging and draining the liquid in the second containing portion 21.

以上のような本実施形態の細胞濃縮用容器10によれば、容器本体11が可撓性を有するので、密封状態で容積を増減でき、簡易な構造で閉鎖系を保ちつつ細胞濃縮のための各操作を行うことができる。 According to the cell concentration container 10 of the present embodiment as described above, since the container body 11 has flexibility, the volume can be increased or decreased in a sealed state, and the cell concentration can be performed while maintaining a closed system with a simple structure. Each operation can be performed.

本実施形態の細胞濃縮用容器10では、容器本体11には、第1収容部17の一端側の底部19に第2収容部21が連通して設けられ、第1収容部17の一端側の底部19が第2収容部21側に下り勾配で設けられ、さらに第2収容部21の一端部に排出部12が設けられて先端29から細胞濃縮液を抜き取り可能に閉塞している。 In the cell concentration container 10 of the present embodiment, the container body 11 is provided with the second storage portion 21 communicating with the bottom 19 on the one end side of the first storage portion 17, and is provided on the one end side of the first storage portion 17. The bottom portion 19 is provided on the side of the second accommodating portion 21 with a downward slope, and a discharge portion 12 is provided at one end of the second accommodating portion 21 so that the cell concentrate can be extracted from the tip 29 and closed.

そのため、遠心分離により目的細胞が一端側に沈降して集まることで、第2収容部21における排出部12の先端29から抜き取り易い位置に細胞濃縮液が生成する。よって、この細胞濃縮液を短い距離で容易に且つ無駄なく抜き取ることができる。しかも細胞濃縮液を先端29から直接抜き取るため、可撓性で変形し易い容器本体11であってもこの変形に影響されずに抜き取り操作を行うことができる。
従って、本実施形態の細胞濃縮用容器10によれば、簡易な構造で閉鎖系を保ちつつ細胞濃縮を行うことができるとともに、細胞濃縮液を容易に無駄なく確実に抜き取ることが可能である。
Therefore, by centrifuging, the target cells settle to one end side and gather, so that the cell concentrate is generated at a position where it can be easily extracted from the tip 29 of the discharge portion 12 in the second storage portion 21. Therefore, this cell concentrate can be easily and without waste in a short distance. Moreover, since the cell concentrate is directly extracted from the tip 29, even the flexible and easily deformable container body 11 can be extracted without being affected by this deformation.
Therefore, according to the cell concentration container 10 of the present embodiment, it is possible to concentrate cells while maintaining a closed system with a simple structure, and it is possible to easily and surely withdraw the cell concentrate without waste.

本実施形態では、細胞濃縮用容器10で多量の細胞懸濁液から少量の細胞濃縮液を生成するため、可撓性の容器本体11が大きくて取り扱う際に各種の変形が生じ易く、その一方で第2収容部21が小さく形成されている。そのため、第2収容部21の一端部に設けられた排出部12の先端29から、抜取具41により細胞濃縮液を抜き取ることで、大きく変形し易い第1収容部17に関係なく、細胞濃縮液を抜き取り操作することができ、細胞濃縮液を容易に無駄なく抜き取ることが可能である。ここでは目的細胞が単核球であり、単核球が濃縮された細胞濃縮液を無駄なく抜き取って有効に使用することができる。 In the present embodiment, since a small amount of cell concentrate is produced from a large amount of cell suspension in the cell concentration container 10, various deformations are likely to occur when the flexible container body 11 is large and handled. The second accommodating portion 21 is formed small. Therefore, by extracting the cell concentrate from the tip 29 of the discharge portion 12 provided at one end of the second accommodating portion 21 with the extraction tool 41, the cell concentrate is easily deformed regardless of the first accommodating portion 17. Can be extracted, and the cell concentrate can be easily extracted without waste. Here, the target cell is a mononucleosis, and the cell concentrate in which the mononucleosis is concentrated can be extracted without waste and used effectively.

本実施形態の細胞濃縮用容器10によれば、第2収容部21が可撓性チューブにより形成され、排出部12が第2収容部21を外側から加圧して閉塞する構成であれば、外側から第2収容部21を容易に開閉して細胞濃縮液を抜き取ることができ、操作性がよい。 According to the cell concentration container 10 of the present embodiment, if the second storage portion 21 is formed of a flexible tube and the discharge portion 12 pressurizes and closes the second storage portion 21 from the outside, the outside The second accommodating portion 21 can be easily opened and closed to drain the cell concentrate, and the operability is good.

本実施形態の細胞濃縮用容器10によれば、排出部12が先端29に流路31を有する硬質部材33を備え、抜取具41が貫通可能な弾性部材35により流路31が閉塞されている。そのため、抜取具41を弾性部材35に貫通させることで容易に細胞濃縮液を抜き取ることができ、その際、硬質部材33を支持して操作することができるので、操作性を向上できる。
また、硬質部材33の内径からなる流路31に弾性部材35を装着しているので、嵌合代、すなわち、硬質部材33の内径に対する弾性部材35の封止力をコントロールすることが容易であり、確実な封止を行うことができる。これにより排出部12に高い遠心力がかかる場合にも確実な封止が可能である。
According to the cell concentration container 10 of the present embodiment, the discharge portion 12 includes a hard member 33 having a flow path 31 at the tip 29, and the flow path 31 is blocked by an elastic member 35 through which the extraction tool 41 can penetrate. .. Therefore, the cell concentrate can be easily extracted by passing the extraction tool 41 through the elastic member 35, and at that time, the hard member 33 can be supported and operated, so that the operability can be improved.
Further, since the elastic member 35 is mounted on the flow path 31 formed of the inner diameter of the hard member 33, it is easy to control the fitting allowance, that is, the sealing force of the elastic member 35 with respect to the inner diameter of the hard member 33. , Reliable sealing can be performed. As a result, even when a high centrifugal force is applied to the discharge unit 12, reliable sealing is possible.

本実施形態の細胞濃縮用容器10では、弾性部材35にスリット43が設けられているため、抜取具41が太くても弾性部材35を貫通させることができ、細胞濃縮液をより大径の流路31から抜き取ることができ、抜き取る際に細胞に損傷等を与えることを防止できる。 In the cell concentration container 10 of the present embodiment, since the elastic member 35 is provided with the slit 43, the elastic member 35 can be penetrated even if the extraction tool 41 is thick, and the cell concentrate can be flowed in a larger diameter. It can be extracted from the road 31 and can prevent damage to cells during extraction.

本実施形態の細胞濃縮用容器10によれば、弾性部材35を貫通した抜取具41の先端開口41aが弾性部材35の隣接位置に配置可能に構成されている。そのため細胞濃縮液を抜取具41により抜き取る際、第2収容部21の細胞濃縮液を底まで抜き取ることができ、細胞濃縮液が内部に残留し難く、無駄なく抜き取ることができる。 According to the cell concentration container 10 of the present embodiment, the tip opening 41a of the extraction tool 41 penetrating the elastic member 35 can be arranged at a position adjacent to the elastic member 35. Therefore, when the cell concentrate is extracted by the extraction tool 41, the cell concentrate of the second accommodating portion 21 can be extracted to the bottom, and the cell concentrate is unlikely to remain inside and can be extracted without waste.

なお上記実施形態は、本発明の範囲内において適宜変更可能である。
上記実施形態では、目的細胞の例として単核球の例について説明したが、細胞懸濁液を遠心分離することで、沈降して細胞濃縮可能な細胞であれば特に限定されない。例えば浮遊系の細胞であっても接着性細胞であってもよく、また各種の手法により培養された培養細胞であっても、各種の細胞スフェロイド等であってもよい。
また上記実施形態では、細胞濃縮用容器10の容器本体11として、第1収容部17が可撓性フィルムからなるバッグにより構成され、第2収容部21がチューブにより構成され、両者が接合された例について説明したが、第1収容部17及び第2収容部21が連続した可撓性フィルムにより一体に形成された容器であってよい。例えば第1収容部17の一端側に縮小部25が設けられるとともに、縮小部25の下端に第1収容部17より幅狭の第2収容部21が設けられた連続したフィルムからなる容器本体11を構成することも可能である。その場合、第2収容部21の一方側の端部に、例えば硬質部材33を気密に接合して貫通流路31を第2収容部21の内部と連通させてもよい。
The above embodiment can be appropriately modified within the scope of the present invention.
In the above embodiment, the example of mononucleosis has been described as an example of the target cell, but the cell is not particularly limited as long as it is a cell that can be precipitated and concentrated by centrifuging the cell suspension. For example, it may be a floating cell, an adhesive cell, a cultured cell cultured by various methods, or various cell spheroids.
Further, in the above embodiment, as the container body 11 of the cell concentration container 10, the first storage portion 17 is composed of a bag made of a flexible film, the second storage portion 21 is composed of a tube, and both are joined. Although an example has been described, the container may be a container in which the first accommodating portion 17 and the second accommodating portion 21 are integrally formed by a continuous flexible film. For example, a container body 11 made of a continuous film in which a reduction portion 25 is provided on one end side of the first accommodation portion 17 and a second accommodation portion 21 narrower than the first accommodation portion 17 is provided at the lower end of the reduction portion 25. It is also possible to configure. In that case, for example, a hard member 33 may be airtightly joined to one end of the second accommodating portion 21 so that the through flow path 31 communicates with the inside of the second accommodating portion 21.

さらに上記実施形態では、排出部12として、硬質部材33の流路31を弾性部材35で閉塞してキャップ37で密封した構造と、クレンメ等のクリップ39で第2収容部21の端部を加圧して閉鎖した構造と、との両方を設けた例について説明したが、何れか一方の構造のみを設けることも可能である。
また排出部12は開閉可能な構成としてもよく、例えばスクリューキャップによる開閉機構、針通栓、閉塞栓付コネクタなどとし、排出部12と第2収容部21との間で外側から閉塞する構成とすることも可能である。その場合、排出部からの漏れを確実に防止することができ、排出部12に高い遠心力がかかる場合に有効である。
さらに、上記実施形態では、第2収容部21の長さが比較的短いものについて説明したが、第2収容部21を主として可撓性チューブで構成する場合、第2収容部21として、より長い可撓性チューブを採用することも可能である。遠心分離機にセットするときには、可撓性チューブからなる第2収容部21が閉塞されないように曲げて、排出部12を容器の上方や遠心分離時の回転中心側の位置に保持し、その状態で遠心分離するようにしても良い。この場合、排出部12が容器上方や遠心分離時の回転中心方向に位置するので、排出部12に掛かる遠心力を緩和することができる。
Further, in the above embodiment, as the discharge portion 12, a structure in which the flow path 31 of the hard member 33 is closed by the elastic member 35 and sealed by the cap 37, and the end portion of the second accommodating portion 21 are added by a clip 39 such as a clamp. An example in which both a pressure-closed structure and a structure are provided has been described, but it is also possible to provide only one of the structures.
Further, the discharge unit 12 may be configured to be openable and closable, for example, an opening / closing mechanism using a screw cap, a needle plug, a connector with a plug, and the like, and a configuration in which the discharge unit 12 and the second accommodating unit 21 are closed from the outside. It is also possible to do. In that case, leakage from the discharge unit can be reliably prevented, which is effective when a high centrifugal force is applied to the discharge unit 12.
Further, in the above embodiment, the length of the second accommodating portion 21 is relatively short, but when the second accommodating portion 21 is mainly composed of a flexible tube, the length of the second accommodating portion 21 is longer. It is also possible to adopt a flexible tube. When setting in the centrifuge, the second accommodating portion 21 made of a flexible tube is bent so as not to be blocked, and the discharging portion 12 is held above the container or at a position on the rotation center side during centrifugation, and is in that state. You may centrifuge with. In this case, since the discharge unit 12 is located above the container or in the direction of the center of rotation during centrifugation, the centrifugal force applied to the discharge unit 12 can be relaxed.

次に、本発明の実施例について説明する。
図1に示すような細胞濃縮用容器10を用い、末梢血から単核球を濃縮及び回収した。
細胞濃縮用容器10は、第1収容部17がエチレン酢酸ビニル共重合体のフィルムからなり、第2収容部21がポリ塩化ビニルのチューブからなり、接合部23がポリエチレンの成形体からなる。この細胞濃縮用容器10は予めガンマ線照射により滅菌した。
Next, examples of the present invention will be described.
Mononucleosis was concentrated and recovered from peripheral blood using the cell concentration container 10 as shown in FIG.
In the cell concentration container 10, the first container 17 is made of a film of ethylene-vinyl acetate copolymer, the second container 21 is made of a polyvinyl chloride tube, and the joint 23 is made of a polyethylene molded product. The cell concentration container 10 was sterilized in advance by gamma ray irradiation.

針21GセーフタッチPSVセット(商標)を用いて、CPDA液入り血液バッグに120mL末梢血を採取した。なお、CPDA液入り血液バッグには、CPDA液16.8mLが入っていた。
末梢血5mLをサンプリングして血液成分測定を行い、白血球数、リンパ球数、単球数を測定した。白血球数、リンパ球数から末梢血110mL中の総単核球数を計算したところ、有核細胞数は6700cells/μLで、120mL中では804cells×10/120mLであった。また単核球数は2770cells/μLで、120mL中で332.4cells×10/120mLであった。
120 mL peripheral blood was collected in a blood bag containing CPDA solution using a needle 21G Safe Touch PSV Set ™. The blood bag containing the CPDA solution contained 16.8 mL of the CPDA solution.
Blood components were measured by sampling 5 mL of peripheral blood, and the white blood cell count, lymphocyte count, and monocyte count were measured. White blood cell count, the calculated total number of mononuclear cells in peripheral blood 110mL from lymphocyte count, number of nucleated cells in 6700cells / μL, is in 120mL was 804cells × 10 6 / 120mL. The mononuclear cell count is 2770cells / μL, was 332.4cells × 10 6 / 120mL in 120 mL.

CPDA液入り血液バッグのCPDA液含有末梢血136.8mLから、120mLを遠心分離機(SEPAX2、商標)の分離に用いることから、遠心分離機(SEPAX2、商標)での分離前の末梢血110mLに含まれる細胞数は、それぞれ有核細胞数が646.5cells×10/110mLで、単核球数が267.3 cells×10/110mLとなった。 From 136.8 mL of CPDA solution-containing peripheral blood in a blood bag containing CPDA solution, 120 mL is used for separation of the centrifuge (SEPAX2, trademark) to 110 mL of peripheral blood before separation by the centrifuge (SEPAX2, trademark). the number of cells contained, the number of nucleated cells, respectively 646.5cells × 10 6 / 110mL, mononuclear cell counts became 267.3 cells × 10 6 / 110mL.

遠心分離機(SEPAX2、商標)により単核球の分離及び回収を行った。
CPDA液含有末梢血120mL(末梢血量は110mL)、ヒトリンパ球分離用媒体(Ficoll−Paque PREMIUM 1.073、GEヘルスケア社製、商標)100 mL、生理食塩水1000mLを用いて、遠心分離機(SEPAX2、商標)にセットし、単核球の分離の工程プログラムを実行して、回収用バッグに45mLの単核球懸濁液を回収した。
Mononucleosis was separated and recovered by a centrifuge (SEPAX2, trademark).
Centrifuge using 120 mL of CPDA solution-containing peripheral blood (peripheral blood volume is 110 mL), 100 mL of human lymphocyte separation medium (Ficoll-Paque PREMIUM 1.073, GE Healthcare, trademark), and 1000 mL of physiological saline. A 45 mL mononuclear cell suspension was recovered in a recovery bag by running a process program for separating mononuclear cells in (SEPAX2, trademark).

詳細には、ヒトリンパ球分離用媒体91mLを遠心チャンバーへ導入し、CPDA液含有末梢血を遠心チャンバーに導入し、合計量211mLとし、15分間、所定の遠心力を印加し、遠心分離を行った。バフィーコート及び血漿を退避用バッグへ一時退避させて、赤血球を廃棄した。 Specifically, 91 mL of a medium for separating human lymphocytes was introduced into a centrifugal chamber, and peripheral blood containing CPDA solution was introduced into the centrifugal chamber to make a total volume of 211 mL, and a predetermined centrifugal force was applied for 15 minutes to perform centrifugation. .. The buffy coat and plasma were temporarily evacuated to a evacuation bag, and the red blood cells were discarded.

その後、生理食塩水で遠心チャンバーを洗浄した後、退避用バッグからバフィーコート及び血漿を遠心チャンバーへ戻して生理食塩水を加えて遠心分離し、上清みを廃棄した。遠心チャンバーの洗浄及び生理食塩水を加えた遠心分離の操作を2回繰り返した。
生成物に生理食塩水を加えて45mLにして回収用バッグに収容した。
回収用バッグからシリンジで細胞懸濁液45mLを回収し、細胞懸濁液2mLを無菌試験用容器にサンプリングして無菌試験に供した。その結果、菌の検出は認められなかった。
Then, after washing the centrifuge chamber with physiological saline, the buffy coat and plasma were returned from the evacuation bag to the centrifugal chamber, physiological saline was added and centrifuged, and the supernatant was discarded. The operation of washing the centrifuge chamber and centrifuging with saline was repeated twice.
Physiological saline was added to the product to make 45 mL and placed in a collection bag.
45 mL of the cell suspension was collected from the collection bag with a syringe, and 2 mL of the cell suspension was sampled in a sterility test container and subjected to the sterility test. As a result, no bacteria were detected.

また細胞懸濁液1mLをサンプリングし、多項目自動血球分析装置(XN−Series、シメックス社製、商標)で血液成分測定を行い、リンパ球数、単球数を測定した。上記データを用いて細胞回収率を算出し、トリパンブルー試薬を用いて細胞生存率を計測した。
その結果、有核細胞数は4208cells/μLで、45mL中では189.4cells×10/45mLであった。単核球数は3970cells/μLで、45mL中では178.7cells×10/45mL、42mL中では166.7cells×10/42mLであった。
In addition, 1 mL of the cell suspension was sampled, and blood components were measured with a multi-item automatic blood cell analyzer (XN-Series, manufactured by Simex, trademark) to measure the number of lymphocytes and the number of monocytes. The cell recovery rate was calculated using the above data, and the cell viability was measured using the trypan blue reagent.
As a result, number of nucleated cells in 4208cells / μL, is in 45mL was 189.4cells × 10 6 / 45mL. Mononuclear cell counts in 3970cells / μL, is in 45mL 178.7cells × 10 6 / 45mL, is in 42mL was 166.7cells × 10 6 / 42mL.

細胞回収率を計算すると(178.7 cells×10)/(267.3cells×10)×100で66.8%となった。また生存率は99.5%であった。
なお細胞懸濁液45mLの一部を無菌試験用容器にサンプリングして無菌試験に供したところ、菌の検出は認められなかった。
Calculating the cell recovery rate (178.7 cells × 10 6) / In (267.3cells × 10 6) × 100 was 66.8%. The survival rate was 99.5%.
When a part of 45 mL of the cell suspension was sampled in a sterility test container and subjected to the sterility test, no bacteria were detected.

次に、図1に示すような細胞濃縮用容器10を用いて細胞濃縮を行った。
細胞懸濁液42mLを収容した細胞濃縮用容器10に83mLの生理食塩水を注入し、全量125mLとした。細胞濃縮用容器10を図3に示す形状保持アダプタを装着してテーブルトップ冷却遠心機 5500(株式会社久保田製作所製)にセットし、20度に設定したうえで、650Gで10分間遠心分離して細胞濃縮を行った。細胞濃縮後に液漏れがないことを確認した。
Next, cell concentration was performed using the cell concentration container 10 as shown in FIG.
83 mL of physiological saline was injected into the cell concentration container 10 containing 42 mL of the cell suspension to make a total volume of 125 mL. The cell concentration container 10 is attached to the shape-retaining adapter shown in FIG. 3, set in a tabletop cooling centrifuge 5500 (manufactured by Kubota Seisakusho Co., Ltd.), set to 20 degrees, and centrifuged at 650 G for 10 minutes. Cell concentration was performed. It was confirmed that there was no liquid leakage after cell concentration.

細胞濃縮後、沈殿した細胞が散らないよう注意し、懸垂部15を利用して細胞濃縮用容器10を吊り下げ、第1収容部17の外側からクランプ51で図1に仮想線で示すように横断する位置を挟むことで、第1収容部17の内部と第2収容部21の内部とを液密に仕切り、第2収容部21に細胞濃縮液を収容した。
このときクランプ51から排出部12までの第2収容部21に収容される細胞濃縮液の液量が4mL以下になるようにした。
After concentrating the cells, be careful not to disperse the precipitated cells, suspend the cell concentration container 10 using the suspension portion 15, and use the clamp 51 from the outside of the first storage portion 17 as shown by a virtual line in FIG. By sandwiching a crossing position, the inside of the first storage portion 17 and the inside of the second storage portion 21 were liquid-tightly partitioned, and the cell concentrate was stored in the second storage portion 21.
At this time, the amount of the cell concentrate contained in the second storage section 21 from the clamp 51 to the discharge section 12 was adjusted to 4 mL or less.

第1収容部17の他端部に設けられた連結チューブ13からクランプ51上部の上清みを抜き取った。
この上清みからエンドトキシン測定用サンプルを回収し、エンドトキシン測定システム(Endosafe(R)−PTS (PTS100)、登録商標、和研薬株式会社製)によりエンドトキシン量を測定したところ、測定値が0.05 EU/mL未満であり、日本薬局方の髄腔に投与する医薬品の基準のエンドトキシン値を満足するものであった。なおSample RT CVは0%、Spike RT CVは10.6%、Spike Recoveryは92%であった。
The supernatant on the upper part of the clamp 51 was extracted from the connecting tube 13 provided at the other end of the first accommodating portion 17.
A sample for endotoxin measurement was collected from this supernatant, and the amount of endotoxin was measured by an endotoxin measurement system (Endosafe (R) -PTS (PTS100), registered trademark, manufactured by Waken Yakuhin Co., Ltd.). It was less than 05 EU / mL, which satisfied the standard endotoxin level of the drug to be administered to the medullary cavity of the Japanese Pharmacy. The Sample RT CV was 0%, the Spike RT CV was 10.6%, and the Spike Recovery was 92%.

その後、クランプ51を外して濃縮細胞をタッピング等で外部から解して懸濁させた。
シリンジを排出部12の先端から挿入して弾性部材35を貫通させ、シリンジの先端開口41aを第2収容部21の内部における弾性部材35の隣接位置に配置し、細胞懸濁液をシリンジで抜き取った。シリンジ内の細胞懸濁液の体積を測定したところ、採取量は4mLであった。
Then, the clamp 51 was removed, and the concentrated cells were loosened from the outside by tapping or the like and suspended.
A syringe is inserted from the tip of the discharge portion 12 to penetrate the elastic member 35, the tip opening 41a of the syringe is arranged at a position adjacent to the elastic member 35 inside the second accommodating portion 21, and the cell suspension is extracted with the syringe. It was. When the volume of the cell suspension in the syringe was measured, the collected amount was 4 mL.

得られた細胞濃縮液の単核球数を測定した。
シリンジ内の細胞懸濁液の一部をサンプリングし、多項目自動血球分析装置(XN−Series、シメックス社製、商標)で血液成分測定を行い、リンパ球数、単球数を測定した。上記データを用いて単核球の細胞回収率を算出し、トリパンブルー試薬を用いて細胞生存率を計測した。
その結果、有核細胞数は40304cells/μLで、4mL中では161.2cells×10/4mLであった。単核球数は37851cells/μLで、4mL中では151.4cells×10/4mLであった。
The mononucleosis count of the obtained cell concentrate was measured.
A part of the cell suspension in the syringe was sampled, blood components were measured with a multi-item automatic blood cell analyzer (XN-Series, manufactured by Simex, trademark), and the lymphocyte count and monocyte count were measured. The cell recovery rate of mononucleosis was calculated using the above data, and the cell viability was measured using the trypan blue reagent.
As a result, number of nucleated cells in 40304cells / μL, is in 4mL was 161.2cells × 10 6 / 4mL. Mononuclear cell counts in 37851cells / μL, was 151.4cells × 10 6 / 4mL is in 4 mL.

細胞回収率を計算すると、(151.4cells×10)/(166.7cells×10)×100=90.8%となった。また生存率は99%であった。
なお、シリンジ内の細胞濃縮液の一部を無菌試験用容器にサンプリングして無菌試験に供したところ、菌の検出は認められなかった。
The cell recovery rate was calculated to be (151.4 cells × 10 6 ) / (166.7 cells × 10 6 ) × 100 = 90.8%. The survival rate was 99%.
When a part of the cell concentrate in the syringe was sampled in a container for sterility test and subjected to the sterility test, no bacteria were detected.

以上における各工程での細胞数と細胞回収率と細胞生存率とを表1にまとめた。

Figure 2020162447
Table 1 summarizes the number of cells, the cell recovery rate, and the cell survival rate in each step in the above.
Figure 2020162447

またエンドトキシン測定量及び無菌試験結果を表2にまとめた。

Figure 2020162447
Table 2 summarizes the endotoxin measurement amount and the sterility test results.
Figure 2020162447

表1から明らかなように、末梢血から遠心分離機(SEPAX2、商標)で単核球懸濁液を回収し、細胞濃縮用容器10により単核球濃縮液の回収を行ったところ、4mL以下で回収することができ、細胞回収率は90.8%と高回収率であった。
末梢血採取後、遠心分離機(SEPAX2、商標)での細胞分離、細胞濃縮用容器10での細胞濃縮、最終製品であるシリンジへの充填において、安全性の確認として、エンドトキシン測定、無菌試験を実施したが、特に問題となる結果は無かった。
As is clear from Table 1, the mononucleosis suspension was recovered from the peripheral blood by a centrifuge (SEPAX2, trademark), and the mononucleosis concentrate was recovered by the cell concentration container 10 and found to be 4 mL or less. The cell recovery rate was as high as 90.8%.
After collecting peripheral blood, endotoxin measurement and sterility test are performed to confirm safety in cell separation with a centrifuge (SEPAX2, trademark), cell concentration in a cell concentration container 10, and filling into a syringe, which is the final product. It was carried out, but there were no particular problematic results.

10 細胞濃縮用容器
11 容器本体
12 排出部
13 連結チューブ
15 懸垂部
17 第1収容部
19 底部
21 第2収容部
23 接合部
25 縮小部
27 筒部
29 先端
31 流路
33 硬質部材
35 弾性部材
37 キャップ
39 クリップ
41 抜取具
41a 先端開口
43 スリット
45 アダプタ
47 外周面
48 傾斜面
49 内部配置部
51 クランプ
10 Cell concentration container 11 Container body 12 Discharge part 13 Connecting tube 15 Suspended part 17 First accommodating part 19 Bottom 21 Second accommodating part 23 Joint part 25 Shrinking part 27 Cylinder part 29 Tip 31 Flow path 33 Hard member 35 Elastic member 37 Cap 39 Clip 41 Extractor 41a Tip opening 43 Slit 45 Adapter 47 Outer surface 48 Inclined surface 49 Internal arrangement 51 Clamp

Claims (6)

可撓性の容器本体の一端部に排出部を有し、目的細胞を含有する細胞懸濁液が密封状態で収容されて遠心分離されることで、一端側に前記目的細胞が沈降して細胞濃縮液が生成される細胞濃縮用容器であって、
前記容器本体は、第1収容部と、前記第1収容部の前記一端側の底部に該第1収容部と連通して設けられて前記細胞濃縮液が貯留される第2収容部と、を有し、
前記第1収容部の前記底部は、前記第2収容部側に向けて下り勾配に形成され、
前記排出部は、前記第2収容部の前記一端部に設けられて先端から前記細胞濃縮液を抜き取り可能に閉塞されている、細胞濃縮用容器。
A cell suspension containing target cells is contained in a sealed state and centrifuged at one end of a flexible container body, so that the target cells settle on one end and the cells A cell concentration container from which a concentrate is produced.
The container body includes a first accommodating portion and a second accommodating portion provided at the bottom of the first accommodating portion on one end side in communication with the first accommodating portion to store the cell concentrate. Have and
The bottom portion of the first accommodating portion is formed in a downward slope toward the second accommodating portion side.
The cell concentration container is provided at one end of the second storage unit and is closed so that the cell concentrate can be extracted from the tip thereof.
前記目的細胞が単核球である、請求項1に記載の細胞濃縮用容器。 The cell concentration container according to claim 1, wherein the target cell is a mononucleosis. 前記第2収容部は可撓性チューブにより形成され、前記排出部は前記第2収容部を外側から加圧して閉塞されている、請求項1又は2に記載の細胞濃縮用容器。 The cell concentration container according to claim 1 or 2, wherein the second accommodating portion is formed of a flexible tube, and the discharging portion is closed by pressurizing the second accommodating portion from the outside. 前記排出部は流路を有する硬質部材を備え、抜取具を貫通させることができる弾性部材により前記流路が閉塞されている、請求項1乃至3の何れかに記載の細胞濃縮用容器。 The cell concentration container according to any one of claims 1 to 3, wherein the discharge portion includes a hard member having a flow path, and the flow path is blocked by an elastic member capable of penetrating the extraction tool. 前記弾性部材にスリットが設けられている、請求項4に記載の細胞濃縮用容器。 The cell concentration container according to claim 4, wherein the elastic member is provided with a slit. 前記弾性部材を貫通した前記抜取具の先端開口を、前記弾性部材の隣接位置に配置可能に構成されている、請求項4又は5に記載の細胞濃縮用容器。
The cell concentration container according to claim 4 or 5, wherein the tip opening of the extraction tool penetrating the elastic member can be arranged at a position adjacent to the elastic member.
JP2019064476A 2019-03-28 2019-03-28 Container for cell concentration Active JP7226738B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2019064476A JP7226738B2 (en) 2019-03-28 2019-03-28 Container for cell concentration
PCT/JP2020/012533 WO2020196347A1 (en) 2019-03-28 2020-03-19 Container for concentrating cells

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2019064476A JP7226738B2 (en) 2019-03-28 2019-03-28 Container for cell concentration

Publications (2)

Publication Number Publication Date
JP2020162447A true JP2020162447A (en) 2020-10-08
JP7226738B2 JP7226738B2 (en) 2023-02-21

Family

ID=72611941

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019064476A Active JP7226738B2 (en) 2019-03-28 2019-03-28 Container for cell concentration

Country Status (2)

Country Link
JP (1) JP7226738B2 (en)
WO (1) WO2020196347A1 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009189280A (en) * 2008-02-13 2009-08-27 Olympus Corp Centrifugal separation container and centrifugal separation apparatus
WO2012017663A1 (en) * 2010-08-04 2012-02-09 財団法人ヒューマンサイエンス振興財団 Mononuclear cell separation column, mononuclear cell separation system, method for separating out mononuclear cells, mononuclear cells, and drug for internal administration
JP2012044876A (en) * 2010-08-24 2012-03-08 Olympus Corp Centrifugal container
JP2012510272A (en) * 2008-12-01 2012-05-10 バクスター・インターナショナル・インコーポレイテッド Apparatus and method for treating biological material
JP2015057287A (en) * 2014-11-25 2015-03-26 独立行政法人国立がん研究センター Centrifugal separation tool

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009189280A (en) * 2008-02-13 2009-08-27 Olympus Corp Centrifugal separation container and centrifugal separation apparatus
JP2012510272A (en) * 2008-12-01 2012-05-10 バクスター・インターナショナル・インコーポレイテッド Apparatus and method for treating biological material
WO2012017663A1 (en) * 2010-08-04 2012-02-09 財団法人ヒューマンサイエンス振興財団 Mononuclear cell separation column, mononuclear cell separation system, method for separating out mononuclear cells, mononuclear cells, and drug for internal administration
JP2012044876A (en) * 2010-08-24 2012-03-08 Olympus Corp Centrifugal container
JP2015057287A (en) * 2014-11-25 2015-03-26 独立行政法人国立がん研究センター Centrifugal separation tool

Also Published As

Publication number Publication date
JP7226738B2 (en) 2023-02-21
WO2020196347A1 (en) 2020-10-01

Similar Documents

Publication Publication Date Title
JP5555356B2 (en) Blood bag system
KR101265243B1 (en) Liquid component collecting device
MXPA01013377A (en) Blood processing set including an integrated blood sampling system.
AU2318199A (en) Systems and methods for processing and storing placenta/umbilical cord blood
US11745182B2 (en) Collapsible centrifugation vial system and method
US6730071B1 (en) Collection, storage, transportation and sampling system and method of use thereof
EA015377B1 (en) Biological fluid processing method and apparatus (variants)
KR20150034283A (en) Mobile system for separating donor blood by means of gravitational force
JP6256352B2 (en) Blood component separation and storage device and method for preparing platelet-rich plasma
WO2013175797A1 (en) Cell separation bag, cell separation method, and cell separation system
US9440243B2 (en) Apparatus for centrifugation and methods therefore
US11911553B2 (en) Systems and methods for concentrating cells with a syringe and a centrifuge
WO2020196347A1 (en) Container for concentrating cells
CN202036601U (en) Pocket type blood ingredient separator
JPH07328099A (en) Bag connector and separating/shifting method for blood constituent
US9372132B2 (en) Blood component sampling system and blood processing systems and methods employing same
CN204601195U (en) Bag for collecting cord blood
RU112043U1 (en) BLOOD CONTAINER AND ITS COMPONENTS
WO2019108937A1 (en) Apparatus and method for centrifuging a biologic
KR101433821B1 (en) Platelet concentrate set of automatically inserting anticoagulant
WO2013146505A1 (en) Device for separating blood components and method of separating blood components
RU2297251C2 (en) Method for taking donor blood and dividing it into components
US20210369943A1 (en) Vessel and device for recovering and preparing adipose tissues
AU2005202959B2 (en) Blood processing set including an integrated blood sampling system
JP2013203659A (en) Blood treatment filter and blood circuit

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210625

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220524

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220722

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220921

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230110

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230201

R150 Certificate of patent or registration of utility model

Ref document number: 7226738

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150